The incidence of obesity and diabetes, also known as the 'twin epidemics', is a rising global issue, particularly in developed nations. Therefore, cutting-edge therapeutic modalities are required. As the only dual glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) receptor agonist, tirzepatide, also referred to as a 'twincretin', can significantly lower glycemic levels, improve insulin sensitivity, as well as reduce body weight by more than 20% and improve lipid metabolism. On the other hand, we have the USFDA and the EMA approved Semaglutide, a novel second-generation long-acting GLP-1RA for once-weekly subcutaneous administration, as an adjunct to diet and exercise in individuals with type 2 diabetes that is not well controlled. Join us LIVE as renowned endocrinologists Dr. Om Lakhani and Dr. Mayur Agrawal square off to discuss the benefits and drawbacks of each treatment.

Tirzepatide vs Semaglutide in Patients with Type 2 Diabetes

Medical Director & Consultant Endocrinologist, Hormone India Diabetes & Endocrine Centre, Bhopal

Dr. Mayur Agrawal

1

293

7.4K

4.5

Sessions Taken

469

4.5